Mostrar el registro sencillo del ítem
dc.contributor.author | Masri, Ahmad | |
dc.contributor.author | Sherrid, Mark V | |
dc.contributor.author | Abraham, Theodore P | |
dc.contributor.author | Choudhury, Lubna | |
dc.contributor.author | Garcia-Pavia, Pablo | |
dc.contributor.author | Kramer, Christopher M | |
dc.contributor.author | Barriales-Villa, Roberto | |
dc.contributor.author | Owens, Anjali T | |
dc.contributor.author | Rader, Florian | |
dc.contributor.author | Nagueh, Sherif F | |
dc.contributor.author | Olivotto, Iacopo | |
dc.contributor.author | Saberi, Sara | |
dc.contributor.author | Tower-Rader, Albree | |
dc.contributor.author | Wong, Timothy C | |
dc.contributor.author | Coats, Caroline J | |
dc.contributor.author | Watkins, Hugh | |
dc.contributor.author | Fifer, Michael A | |
dc.contributor.author | Solomon, Scott D | |
dc.contributor.author | Heitner, Stephen B | |
dc.contributor.author | Jacoby, Daniel L | |
dc.contributor.author | Kupfer, Stuart | |
dc.contributor.author | Malik, Fady I | |
dc.contributor.author | Meng, Lisa | |
dc.contributor.author | Sohn, Regina L | |
dc.contributor.author | Wohltman, Amy | |
dc.contributor.author | Maron, Martin S | |
dc.date.accessioned | 2024-07-09T14:53:57Z | |
dc.date.available | 2024-07-09T14:53:57Z | |
dc.date.issued | 2024-03-15 | |
dc.identifier.citation | J Card Fail. 2024 Mar 15:S1071-9164(24)00082-4. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/20368 | |
dc.description.abstract | BACKGROUND This open-label phase 2 trial evaluated the safety and efficacy of aficamten in patients with nonobstructive hypertrophic cardiomyopathy (nHCM). METHODS Patients with symptomatic nHCM (left ventricular outflow tract obstruction gradient ≤ 30 mmHg, left ventricular ejection fraction [LVEF] ≥ 60%, N-terminal pro-B-type natriuretic peptide [NT-proBNP] > 300 pg/mL) received aficamten 5-15 mg once daily (doses adjusted according to echocardiographic LVEF) for 10 weeks. RESULTS We enrolled 41 patients (mean ± SD age 56 ± 16 years; 59% female). At Week 10, 22 (55%) patients experienced an improvement of ≥ 1 New York Heart Association class; 11 (29%) became asymptomatic. Clinically relevant improvements in Kansas City Cardiomyopathy Questionnaire Clinical Summary Scores occurred in 22 (55%) patients. Symptom relief was paralleled by reductions in NT-proBNP levels (56%; P < 0.001) and high-sensitivity cardiac troponin I (22%; P < 0.005). Modest reductions in LVEF (mean ± SD) of -5.4% ± 10 to 64.6% ± 9.1 were observed. Three (8%) patients had asymptomatic reduction in LVEF < 50% (range: 41%-48%), all returning to normal after 2 weeks of washout. One patient with prior history of aborted sudden cardiac death experienced a fatal arrhythmia during the study. CONCLUSIONS Aficamten administration for symptomatic nHCM was generally safe and was associated with improvements in heart failure symptoms and cardiac biomarkers. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT04219826. | es_ES |
dc.description.sponsorship | The REDWOOD-HCM trial was funded by Cytokinetics. Medical writing support (editorial support only) was provided by Andrea Schauenburg from Engage Scientific Solutions, UK, and funded by Cytokinetics. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.title | Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución-NoComercial-CompartirIgual 4.0 Internacional | * |
dc.identifier.pubmedID | 38493832 | es_ES |
dc.identifier.doi | 10.1016/j.cardfail.2024.02.020 | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1532-8414 | es_ES |
dc.relation.publisherversion | 10.1016/j.cardfail.2024.02.020 | es_ES |
dc.identifier.journal | Journal of cardiac failure | es_ES |
dc.repisalud.orgCNIC | CNIC::Grupos de investigación::Miocardiopatías Hereditarias | es_ES |
dc.repisalud.institucion | CNIC | es_ES |
dc.rights.accessRights | open access | es_ES |